Table 2.
Parameters | Vitamin D3 group (n = 113) |
Control group (n = 62) |
Total (n = 175) |
P value |
---|---|---|---|---|
Sex | ||||
Male | 69 (61%) | 36 (58%) | 105 (60%) | 0.699 |
Female | 44 (39%) | 26 (42%) | 70 (40%) | |
Age, y, (IQR) | 74 (60–81) | 75 (62–83) | 74 (61–82) | 0.431 |
Age (stratified) | ||||
<50 | 4 (4%) | 4 (6%) | 8 (4%) | 0.378 |
50–65 | 41 (36%) | 15 (24%) | 56 (32%) | 0.101 |
>65 | 68 (60%) | 43 (70%) | 111 (63%) | 0.228 |
25 (OH) D, ng/mL, (IQR) | 6.65 (5.06–9.1) | 7.14 (5.17–8.21) | 6.76 (5.07–8.54) | 0.512 |
Corrected calcium, mg/dL, (IQR) | 8.1 (7.6–8.6) | 8.17 (7.77–8.72) | 8.1 (7.66–8.6) | 0.269 |
Phosphor, mg/dL, (IQR) | 3.1 (2.3–4.1) | 3 (2.4–3.68) | 3.1 (2.4–4) | 0.398 |
Magnesium, mg/dL, (IQR) | 1.8 (1.6–1.9) | 1.9 (1.7–2.1) | 1.8 (1.6–2) | 0.192 |
Albumin, g/dL, (IQR) | 2.7 (2.31–3.19) | 2.73 (2.28–3.36) | 2.7 (2.31–3.2) | 0.819 |
Urea, mg/dL, (IQR) | 55 (34–86) | 46 (31–80) | 50 (34–86) | 0.241 |
Creatine, mg/dL, (IQR) | 1.1 (0.81–1.45) | 1.01 (0.74–1.42) | 1.06 (0.81–1.46) | 0.177 |
AST, U/L, (IQR) | 29 (20–45) | 23 (16–45) | 28 (18–45) | 0.375 |
ALT, U/L, (IQR) | 22 (15–40) | 24 (14–45) | 22 (15–43) | 0.509 |
CRP, mg/dl, (IQR) | 10.8 (6.1–16.4) | 10.6 (5.5–16.25) | 10.85 (6.03–16.46) | 0.465 |
D-dimer, ug/L, (IQR) | 1175 (750–2880) | 1290 (734–3587) | 1230 (750–2960) | 0.248 |
Inhospital mortality (to November 30, 2020) | 43 (38%) | 30 (48%) | 73 (41%) | 0.185 |
Lenght of stay, day, (IQR) | 9 (6–16) | 9 (5–17) | 9 (6–16) | 0.649 |
Endotracheal intubated | 44 (39%) | 31 (50%) | 75 (43%) | 0.157 |
Categorical data shown as number (percentage). Non-normally distributed continuous variables displayed as median (IQR). Chi-square test was used to analyze the categorical variables. Mann–Whitney’s test was used for nonparametric continuous variables.
25 (OH) D 25-hydroxy vitamin D, IQR interquartile range, AST aspartate aminotransferase, ALT Ala-nine aminotransferase, CRP C-reactive protein.